ObsEva (NASDAQ:OBSV) – Equities research analysts at Jefferies Group lowered their Q2 2018 earnings per share estimates for shares of ObsEva in a report released on Wednesday, May 16th. Jefferies Group analyst B. Amin now forecasts that the company will earn ($0.55) per share for the quarter, down from their previous estimate of ($0.48). Jefferies Group also issued estimates for ObsEva’s Q3 2018 earnings at ($0.56) EPS, Q4 2018 earnings at ($0.56) EPS, FY2018 earnings at ($2.21) EPS, FY2019 earnings at ($2.14) EPS, FY2020 earnings at ($2.17) EPS, FY2021 earnings at ($2.99) EPS and FY2022 earnings at ($2.22) EPS.
Several other equities analysts also recently issued reports on the stock. ValuEngine raised shares of ObsEva from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Zacks Investment Research raised shares of ObsEva from a “sell” rating to a “hold” rating in a research note on Thursday, March 15th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of ObsEva in a research note on Friday, March 9th. BMO Capital Markets reaffirmed a “buy” rating and set a $24.00 price target on shares of ObsEva in a research note on Tuesday, February 27th. Finally, Leerink Swann raised their price target on shares of ObsEva from $17.00 to $18.00 and gave the company an “outperform” rating in a research note on Tuesday, February 27th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $20.00.
Shares of ObsEva opened at $13.30 on Monday, MarketBeat reports. The company has a market capitalization of $493.84 million, a price-to-earnings ratio of -5.91 and a beta of 2.82. ObsEva has a fifty-two week low of $5.00 and a fifty-two week high of $15.81.
ObsEva (NASDAQ:OBSV) last issued its earnings results on Wednesday, May 16th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.08).
Several hedge funds have recently added to or reduced their stakes in the company. Sofinnova Management VIII L.L.C. raised its stake in shares of ObsEva by 26.7% during the fourth quarter. Sofinnova Management VIII L.L.C. now owns 4,749,623 shares of the company’s stock valued at $46,356,000 after acquiring an additional 1,000,000 shares during the last quarter. Sofinnova Ventures Inc bought a new position in shares of ObsEva during the first quarter valued at $64,096,000. VHCP Management II LLC raised its stake in shares of ObsEva by 7.8% during the first quarter. VHCP Management II LLC now owns 2,143,843 shares of the company’s stock valued at $28,920,000 after acquiring an additional 155,000 shares during the last quarter. Omega Fund Management LLC bought a new position in shares of ObsEva during the fourth quarter valued at $9,760,000. Finally, First Manhattan Co. bought a new position in ObsEva during the fourth quarter worth $9,760,000. 52.62% of the stock is owned by hedge funds and other institutional investors.
ObsEva Company Profile
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.